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ABSTRACT
Objectives:   The purpose of this qualitative study was to utilize the Capability, Opportunity, 
Motivation - Behavior model (COM-B) to: (1) evaluate athlete knowledge and understanding 
of current asthma-related anti-doping regulations, (2) explore the impact of environmental 
and societal influences on athletes with asthma, and (3) examine athlete perception of 
asthma medication use in competitive sport.
Methods: Semi-structured interviews were conducted with ten competitive endurance 
athletes (five athletes with asthma and five without asthma). Interviews were guided by the 
COM-B model and transcripts were analyzed inductively and deductively using reflexive 
thematic analysis.
Results: Mapping the experiences and perceptions of athletes against an established behavioral 
framework identified that: (1) athletes’ possess limited knowledge and understanding of the 
World Anti-Doping Agency (WADA) Prohibited List and Therapeutic use exemption (TUE) policy 
with respect to asthma medication; (2) the use of sub-optimal diagnostic methods is 
commonplace and increases the risk of misdiagnosis and unnecessary inhaler therapy; (3) 
negative media portrayal of high-profile asthma-related doping allegations impacts public 
opinion and contributes to the perception of wrongdoing within the sporting community.
Conclusion: The novel application of behavioral science highlights several factors that may 
contribute to asthma medication avoidance and promote misuse in competitive sport. The 
findings from this study provide a foundation for the development and implementation of 
targeted education programmes, and it is hoped that employing this approach will ultimately 
improve overall perceptions of asthma treatment in athletes, which is necessary to maintain 
respiratory health, optimize performance and protect the integrity of sport.
Introduction
Multiple high-profile elite endurance athletes have 
been implicated in anti-doping cases for the use of 
asthma medication over the past decade (1,2). In 2016, 
Russian espionage group ‘Fancy Bears’ released con-
fidential data highlighting asthma medication use 
requiring a therapeutic use exemption (TUE) in elite 
sport (3). Although there was no evidence or sugges-
tion of anti-doping rule violations, an apparent resent-
ment appears to be building toward athletes who are 
using asthma medication (4,5). This is despite the fact 
that many recommended and commonly prescribed 
asthma therapies (other than systemic administration 
of corticosteroids to treat acute severe exacerbations) 
are currently permitted by the World Anti-Doping 
Agency (WADA), without requirement for a TUE (for 
review see Allen et  al. 2019) (6).
It has been proposed that the current stigma asso-
ciated with the use of asthma therapy and/or fear of 
breaching anti-doping regulations may actually be 
contributing to therapy non-adherence in some ath-
letes (7). Conversely, the perception of asthma med-
ication providing some form of performance 
enhancement may actually promote the use of unnec-
essary inhaler therapy in some individuals (i.e. athletes 
seeking performance gain). This is despite the fact 
that no definitive evidence currently exists to support 
the performance enhancing properties of asthma med-
ication - particularly when administered at standard 
prescribed inhaled doses (8,9).
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Table 1. study population.
athlEtE sEX aGE (Yrs.) sPort EXPErIEnCE (Yrs.) stanDarD asthma mEDICatIon
1 male 23 triathlon 4 Elite no –
2 male 22 triathlon 4 Elite no –
3 male 25 Cycling 4 sub-elite (regional) Yes Budesonide and salbutamol
4 male 20 Cycling 3 sub-elite (national) no –
5 male 28 Cycling 2 sub-elite (regional) Yes fluticasone propionate and salbutamol
6 male 41 Cycling 5 sub-elite (regional) Yes salbutamol
7 female 23 triathlon 5 Elite Yes Beclomethasone and salbutamol
8 male 19 Cycling 3 sub-elite (national) Yes salbutamol
9 female 24 triathlon 4 Elite no –
10 male 32 Cycling 3 sub-elite (regional) no –
To navigate the complexity surrounding asthma ther-
apy in elite sport and provide insight into the factors 
that may encourage medication avoidance or promote 
misuse, it is important to consider the experiences and 
beliefs of those involved or directly affected. The behav-
ioral system proposed by Michie and colleagues (10) 
in which Capability (C), Opportunity (O) and 
Motivation (M) interact to influence Behavior (B) 
(COM-B) is an established framework that has recently 
been suggested to offer value in this setting (6).
The purpose of this qualitative study was therefore 
to utilize the COM-B model to: (1) evaluate athlete 
knowledge and understanding of current asthma-related 
anti-doping regulations, (2) explore the impact of 
environmental and social influences on athletes with 
asthma, and (3) examine athlete perception of asthma 
medication use in competitive sport.
Methodology
Research design
Face-to-face semi-structured interviews were conducted 
in order to achieve detailed and multi-layered insights 
(11) which were subsequently thematically analyzed and 
mapped to the COM-B model (10). Specifically, the 
model proposes that for any behavior to occur a person 
must have the psychological and physical capability to 
perform a behavior (i.e. knowledge and skill); the phys-
ical (environmental resources) and social opportunity to 
engage in it (i.e. social influences), and they must be 
motivated due to conscious (reflective) and unconscious 
(automatic) brain processes. In the context of athletes 
and asthma medication, it has been proposed that capa-
bility, opportunity and motivation may include, but are 
not limited to, knowledge of the Prohibited List, inter-
action with support personnel or clinicians, and the 
perceived consequences of using asthma medication, 
respectively (6). The COM-B model is a meta-theory 
created from a systematic analysis of nineteen existing 
behavior intervention frameworks (10), that has been 
utilized to investigate other complex behaviors in athletes 
(e.g. nutritional adherence) (12). This study is situated 
within an interpretive paradigm, whereby reality is rec-
ognized as being multi-layered and complex. When 
seeking to understand a phenomenon of interest, inter-
pretivists acknowledge the existence of multiple meanings 
and interpretations (13). In view of the limited knowl-
edge on this topic, a qualitative study was deemed to 
be most appropriate as the methodology can provide a 
valuable source of new ideas and information, particu-
larly in relation to how athletes interpret and interact 
within their competition and training environment. 
Participants received study information and provided 
written informed consent prior to the interviews. All 
interviews were conducted individually, in a convenient 
location by the investigator (HA) and were audio-recorded.
Study population and data collection
Following approval from the local Research Ethics 
Committee, purposive sampling was employed to 
recruit ten athletes (five athletes with a physician 
diagnosis of asthma prescribed inhaler therapy and 
five without asthma) involved in previous research 
studies of the Clinical Exercise and Respiratory 
Physiology Research Group, Leeds Beckett University 
(14,15). Purposive sampling describes the inclusion 
of individuals that provide a rich and detailed insight 
into the research question (16). All athletes had prior 
experience of competitive endurance sport in events 
governed by national anti-doping policy (i.e. potential 
for doping control) but were not currently registered 
on the anti-doping administration management system 
(ADAMS) (Table 1). Semi-structured interviews 
include a short list of guiding questions that are sup-
plemented with follow-up, probing questions, depen-
dant on the participant’s response. In the present 
study, interview questions were guided by the COM-B 
model and tailored specifically for athletes with and 
without asthma. Interview frameworks were initially 
trialed to ensure coherence and the final interview 
guide included questions regarding competition and 
sports performance in order to build rapport (e.g. can 
you tell me about what you do, if anything, to 
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optimize your performance?). Subsequently, experi-
ences and the perception of asthma medication use 
in sport were considered (e.g. ‘You have a diagnosis 
of EIB or asthma and I am keen to hear about your 
experiences of the condition and the treatment’, ‘do 
you feel asthma impacts your ability to participate or 
compete in sport?’ and ‘do you have a peer or fellow 
athlete that uses asthma medication?’) before moving 
on to athletes knowledge and understanding of 
anti-doping rules and regulations (i.e. permitted and 
prohibited asthma medication and the current TUE 
policy) and perceptions of asthma medication use.
Data analysis and interpretation
The interviews lasted approximately one hour in dura-
tion and were transcribed verbatim and managed using 
NVivo 12 (QSR International, Australia). Interview tran-
scripts were analyzed inductively and deductively using 
reflexive thematic analysis (17). First, the transcripts 
were read and re-read, to familiarize with the data and 
assist the second phase of the analysis. Second, initial 
codes were assigned to excerpts of the data. Third, all 
the codes were organized into potential themes that 
reflected the content and meaning of the data; this stage 
was guided by components of the COM-B (10). Fourth, 
the themes were reviewed and refined. Fifth, the themes 
were labeled and defined. Sixth, the analytic narrative 
presented in this manuscript was drafted, reviewed and 
refined. HA and SB engaged in frequent collaborative 
and reflexive discussion and interpretation of the find-
ings throughout the six-stage reflexive thematic analysis 
process. OP and JH contributed to the analytical process 
during phases five and six.
Results
Descriptions of the main findings are organized 
according to the inductive theme, with the associated 
deductive COM-B component shown in parentheses. 
Codes and data assigned to each theme (i.e. athlete 
quotes) are presented in Tables 2–5. The main find-
ings are aligned to the COM-B model in Figure 1.
Asthma medication and anti-doping regulations 
(psychological capability)
Limited knowledge and understanding of the WADA 
Prohibited List and TUE policy with respect to asthma 
Figure 1. the main findings aligned to the Capability, opportunity, motivation model of Behavior (Com-B) (10).
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medication was demonstrated by all athletes. Although 
some athletes acknowledged that common reliever 
therapies such as inhaled salbutamol have a maximum 
permitted dose and that the route of administration 
(i.e. inhaled vs. oral treatment) is relevant in the con-
text of anti-doping - none of the athletes were able 
to articulate any further specific details regarding a 
recommended dosage, strength or permitted limits. 
Likewise, most athletes provided a superficial overview 
concerning the therapeutic effects of reliever and 
maintenance asthma therapy. Despite apparent gaps 
in knowledge, only one athlete with asthma reported 
that they had previously sought guidance from their 
primary care physician or team doctor regarding per-
mitted treatment levels. Those without asthma con-
sidered they may have limited knowledge as they are 
not personally affected by the condition (Table 2).
Screening and detection methods (physical 
opportunity)
Asthma medication was most frequently prescribed 
following a symptom-based diagnosis; i.e. athletes 
reported receiving inhaler therapy having presented 
to their physician reporting troublesome exercise-related 
respiratory symptoms. In the few athletes who under-
went objective testing, baseline spirometry or peak 
expiratory flow (pre-and-post exercise) were the most 
commonly employed diagnostic methods. Although 
one athlete attended an annual asthma review, none 
of the athletes had previously been referred for spe-
cialist testing (i.e. assessment of airway inflammation 
or indirect bronchial provocation) to confirm a diag-
nosis and inform treatment (Table 3).
Media impact and public views (social 
opportunity)
Media portrayal of asthma medication use and TUEs 
in elite sport was considered accusatory and bias by 
all athletes and interpreted as a strategy to attract 
interest and increase readership. The opinion of most 
was that the negative press surrounding recent 
high-profile asthma-related doping allegations impacts 
public opinion and contributes to the perception of 
wrongdoing within the sporting community. Of con-
cern, some athletes confirmed that they had previously 
avoided using asthma medication due to the negative 
associated connotations. Likewise, experiences of peers 
being reluctant to administer asthma medication in 
public due to fear of criticism (i.e. risk of being 
labeled a cheat) were shared (Table 4).
Athlete perception of asthma medication in sport 
(reflexive motivation)
The potential for asthma medication misuse in com-
petitive sport was voiced by athletes with and without 
asthma. Specifically, short-acting inhaled bronchodi-
lators were believed to improve ‘in-exercise’ ventilatory 
function, whereas maintenance therapies (i.e. inhaled 
and oral steroids) were associated with favorable phys-
iological adaptation (i.e. increased muscle mass and 
reduced body fat) and improved recovery time 
between training sessions. Several athletes questioned 
the legitimacy of current prevalence estimates (i.e. 
why do so many elite sportsmen and women have 
asthma?) and expressed concern regarding the poten-
tial to falsify a diagnosis and abuse the TUE system 
with a view to gain an unfair advantage. In contrast, 
some athletes held the belief that athletes with asthma 
should not be disadvantaged due to an underlying 
health condition - and that medication is justified in 
this instance in order to ‘level the playing field’. All 
athletes with asthma raised concern over the risk of 
exacerbation and potential for performance decrement 
if inhaler therapy was to be withheld (Table 5).
Discussion
This study is the first to qualitatively examine athlete 
knowledge of asthma-related anti-doping regulations 
and perceptions of asthma medication use in com-
petitive sport. The novel application of the COM-B 
model (i.e. mapping the experiences and perceptions 
of athletes against an established behavioral frame-
work) has identified several factors that may interact 
to contribute to medication avoidance and promote 
misuse in those seeking performance gain.
The current WADA Prohibited List states that ath-
letes are permitted to administer inhaled salbutamol 
(≤1600 µg in 24-h and 800 µg in 12-h), formoterol 
(≤54 µg in 24-h), salmeterol (≤200 µg in 24-h), 
inhaled vilanterol (≤25 µg in 24-h) and inhaled cor-
ticosteroid maintenance therapy - whereas all other 
inhaled and systematic beta-2-agonists and oral cor-
ticosteroids are prohibited without a TUE (the process 
required to use an otherwise prohibited substance or 
medication dose) (updated annually: www.wada-ama.
org/) (18,19). A key finding from the present study 
was that the majority of athletes possessed limited 
knowledge of anti-doping regulations (i.e. either the 
Prohibited List or TUE policy) with respect to asthma 
therapy, which is in line with similar findings from 
previous anti-doping research in both elite and rec-
reational athletes (20–22).
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Although some athletes in the current study recog-
nized that the dose and route of administration impacts 
the permitted or prohibited status of asthma medication, 
the majority demonstrated uncertainty, which in turn, 
may contribute to medication avoidance (i.e. due to con-
cerns of committing an anti-doping rule violation) or 
inadvertent medication misuse (i.e. reliance on inhaled 
short-acting reliever therapy) (6). In the context of 
asthma management, medication avoidance is recognized 
to impact long-term respiratory health (i.e. deterioration 
in condition) (23), whereas the adverse effects of regular 
high-dose beta-2-agonist therapy have been recognized 
for some time (24); including a heightened risk of severe 
exacerbation and incidence of asthma-related death (25).
Table 2. asthma medication and anti-doping policy (psychological capability).
CoDEs athlEtE QuotEs
Medication • ‘Maybe if I knew a little bit more about it, or maybe if I was asthmatic myself, I’d probably be 
more aware of the level that the lads take and how it would affect the sport’ (athlete 1: non-asthmatic).
• ‘I think it depends if it actually helps, I don’t really know much about the science behind it and 
stuff so if you take too much of something does it actually help you?’ (athlete 2: non-asthmatic).
• ‘I know a bit about exercise-induced asthma and inhalers and how they work and things but I’m 
not too knowledgeable on what advantages it’s gives somebody’ (athlete 6: asthma).
• ‘It’s not like every puff you take brings all your airways further and further out so you get like 
loads more oxygen or something, it just doesn’t work, you don’t change physiology that acutely’ 
(athlete 9: non-asthmatic).
Prohibited List • ‘Not officially, I don’t know. I know that it’s maybe a couple of puffs of the inhalers roughly allowed 
but I wouldn’t know what’s the right amount or wrong amount…I’m quite ignorant to that’ (athlete 
1: non-asthmatic).
• ‘My understanding is that broadly most things that are inhaled are basically fine’ (athlete 5: asthma).
• ‘I remember asking the doctor at the time, you know in principle I’m subject to, you know, is this 
stuff okay?’ (athlete 5: asthma).
• ‘To be honest I’m not certain because I’ve never really looked because I’ve never been… if I’d been 
prescribed it by the doctors or something like that then you look more and check. I know enough 
people use inhalers, but I know the other ones contain steroids. Obviously if I was given anything 
else then I’d look it up but because I’ve never taken it, I’ve not really looked into it. I mean I 
think you can take it, but you have to declare it don’t you…’(athlete 6: asthma).
• ‘I know that I’m allowed to take salbutamol but only up to a certain limit a day, is it 1600 or…800?’ 
(athlete 7: asthma).
• ‘At one point when it felt like it was really bad, (I) got Beclotaide and that is allowed which I 
found surprising because it’s more long acting’ (athlete 7: asthma).
• ‘I just remembered that I also know that there’s some situations where they are banned in con-
junction with other things because their name comes up in the WADA list somewhere else. The 
beta-2-antagonist or something comes up somewhere else as it can be a sign of a masking agent 
if you’ve used it with something else’ (athlete 7: asthma).
• ‘I think a lot of the, what is it, so preventer style medications are sort of prohibited unless you 
have a TUE umm and then even, and then there’s a limit as to how much you can take from 
there, umm, so yes, there might be some completely prohibited I’m not entirely sure but so you 
know sort of, a lot of, sort of, that sort of style medication is’ (athlete 8: asthma).
• ‘Not really…I think that the blue one is okay but you can’t exceed a certain limit and it’s the same 
with the steroids ones as well isn’t it…but I think you have to get TUEs because they’re steroid 
ones but I don’t really know’ (athlete 9: non-asthmatic).
TUEs • ‘To my knowledge a TUE is a… substance that is sanctioned by the governing body for an athlete 
to use because it levels the playing field for that athlete. So, with asthma, your allowed to take 
your inhaler… well I guess the thought process is that it puts that athlete at a level of an athlete 
who doesn’t have asthma’ (athlete 3: asthma).
• ‘I wouldn’t say I’m an expert but I’m vaguely aware that they have to get a doctor to diagnose 
them and say that he needs more than just the normal inhaler and he can have the corticosteroids 
or whatever it is, if it’s a good idea for them’ (athlete 5: asthma).
• ‘I mean, depends what lab tests they’ve got or things like that, I don’t know how you get it, how 
you test somebody really so I’m not that knowledgeable’ (athlete 6: asthma).
• ‘No, I have no idea. I thought you just needed a TUE by going to your doctor and requesting 
that they provide proof for you for whatever symptom it was’ (athlete 7: asthma)
• ‘I’m not entirely sure what the rules are on getting a TUE and which doctors are allowed to diag-
nose you’ (athlete 8: asthma).
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Table 4. media impact and public views (social opportunity).
CoDEs athlEtE QuotEs
Media • ‘I think because he is so good it means that people look for scapegoats for why he’s so good. They don’t look 
at the fact of how much training he does or that fact that he’s got a good somatotype and body type for it, he’s 
naturally lean, or they don’t look at things like that. They just look at he’s doing this performance, he’s on this 
drug and I think they just assume… whereas in the peloton there’s, you know, I remember seeing a stat, there’s 
a crazy amount of people have exercise-induced asthma within the peloton. It’s stupidly high but it’s only people 
like him that are doing exceptionally well that get the sticks. I feel like it’s probably unjust the amount of stick 
that’s he’s getting but it’s because he’s such a high profile, he’s done so well. I feel like if you’re a professional 
cyclist but not doing so well no one cares what you’re on, no you know, no one cares how many different TUEs 
you’ve got but it’s only if you’re the higher level you get the pressure’ (athlete 1: non-asthmatic).
• ‘And then the media have made the hype because, well the media needs to make their hype to make their 
money, that’s what, personally that’s what I feel like’ (athlete 1: non-asthmatic).
• ‘I think that a lot of the cases, when it comes out in the media, especially you find that over here, it’s always 
the British people that get aimed at. That’s what I think anyway’ (athlete 2: non-asthmatic).
• ‘I mean the media only ever seems to hone in when something goes wrong’ (athlete 3: asthma).
• ‘I’m aware of what’s been said in the media that you know obviously cyclists maybe don’t have chronic asthma 
but they’re getting TUEs for chronic asthma which they shouldn’t be…’ (athlete 6: asthma).
• ‘Yeh I’m sure you know that there are people that hear of the way it’s portrayed in the media’ (athlete 8: asthma).
• ‘I don’t think it’s that bigger issue, I think the public are probably given a different idea from the media 
so…’ (athlete 8: asthma).
• ‘I think the only time they’re ever in the news is for bad news, which I can understand cause that’s what 
the media do, they try and obviously sell whatever they’re selling in terms of their publications but at the 
same time there needs to be a bit more of an awareness around what TUEs are, what they are, why they 
are offered to athletes and just a bit more of a balanced view rather than, getting at a guy puffing on an 
inhaler before a stage, then there’s a big question around is that legal, why is that legal and it’s not really a 
balanced argument, it’s very one sided around this is going to give them a performance enhancement because 
of x y and z’ (athlete 10: non-asthmatic).
(Continued)
Table 3. screening and detection methods (physical opportunity).
CoDEs athlEtE QuotEs
Diagnosis • ‘Eventually I got it looked at and they did gave me a blowy reader thing, asked me to track my max 
output or peak output, peak flow I guess you’d call it, consistently throughout the day so in the morning, 
in the evening, but then also do it when I was exercising. After I’d exercised and, on the graph, you 
could see when I had come back from exercise my peak flow would drop drastically from what it was 
in the morning and in the afternoon. They basically deduced it was exercise-induced asthma and put me 
on a prescription of the steroid inhaler 2 puffs in the morning 2 in the evening and then they also gave 
me the blue one as well’ (athlete 3: asthma).
• ‘I think it was before I started cycling, so it’d probably have been around 2014-15, I had a bad cough 
for a while and went to the doctor and said yeh you you’ve got fairly moderate to severe asthma. and 
they gave me the steroid inhaler. It’s a mixed kind of long-term reliever/steroid thing and I was on that 
for a year, and then I went off that and I seemed I’ve always had the blue Ventolin and I’ve still got 
that’ (athlete 5: asthma).
• ‘A few people had sort of said you might have asthma so went to the GP. Sounds like it could be asthma, 
or exercise induced asthma, try an inhaler and I did try the inhaler’ (athlete 6: asthma)
• ‘I reported the symptoms and he said well it sounds like sports induced asthma he says, I’ll prescribe 
you an inhaler and see if that works’ (athlete 6: asthma).
• ‘I went to the doctor about it and he prescribed me a Ventolin inhaler and he didn’t actually tell me 
that it meant I had asthma… he just gave me the inhaler for clearing the cough which it did but then 
I went to the doctor and I mentioned to the doctor when I was I seeing him about something else that 
I had gotten this inhaler for coughing and he said well he wouldn’t have prescribed it if you didn’t have 
cough, if you didn’t have asthma even, if you even if it was initially for the cough or something like 
that. I think that was all that came of it and I didn’t really think that much about it. I was kind of like… 
maybe I do have some form of asthma, but I don’t really know…he said that if they prescribed it, that 
means you’ve got asthma and you should be using it for sport’ (athlete 7: asthma).
• ‘I went to see someone and I said, it wasn’t a repeat prescription because I got my last one from an Irish 
doctor, I’ve got exercise-induced asthma, and my inhalers run out, and I brought my inhaler to show 
them and then they did the spirometry test then he just prescribed me’ (athlete 7: asthma).
• ‘So every year I have to go and see a doctor or a nurse and they assess whether I need continue to have 
a prescription for the following year…it wasn’t anything major, I remember they’d ask me a few questions 
and I’d do a couple of puffs on the peak flow’ (athlete 8: asthma).
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Several challenges exist with respect to the way a 
diagnosis of asthma in athletes is currently established 
(26,27). Indeed, it is now widely recognized that 
self-report respiratory symptoms and baseline lung 
function offer limited diagnostic precision in athletes 
(28,29), and thus objective testing (i.e. indirect bron-
chial provocation) is recommended to avoid misdiag-
nosis and ensure appropriate treatment (30–32). 
Despite this, none of the athletes in the present study 
reported having been referred for specialist testing, 
which corroborates with a prior national survey in 
the UK, conducted by Hull and colleagues (33), who 
found that approximately one-quarter of primary care 
physicians initiated treatment for suspected asthma 
or exercise-induced bronchoconstriction based on clin-
ical history alone without robust objective testing.
The use of sub-optimal diagnostic methods in the 
assessment of athletes reporting respiratory symptoms 
Table 4. Continued.
CoDEs athlEtE QuotEs
Public • ‘I’d say definitely people with the inhalers, you can sometimes see they’ll use it sheepishly, or they’ll go 
around the corner to use it, not because I think they’re hiding it just because they don’t want people to 
think they’re cheating or anything…and because of all the, especially recent stick with [athlete X] having 
exceeding high levels of the asthma drug… salbutamol…yeh it kind of makes it look a bit suspicious. I think 
people are getting a little bit like oh well you know there’s a limit and then people are just using the inhalers 
way too much’ (athlete 1: non-asthmatic).
• ‘I think from the public aspect there will always be a lot of criticism’ (athlete 1: non-asthmatic).
• ‘I think it’s the same with people with inhalers, they might think they need it because they’ve got a medical 
reason, without it it’ll be detrimental to their performance. But people’s stigmatism of you know, mental kind 
of, how they feel about the drug…they might think, ah they’re just cheating, but actually they’re not and 
that might make them feel a little bit… but it’s kind of catch twenty-two because they go and look sheepishly 
using it, hiding…It makes them look guilty but they’re not, they might not be guilty they just don’t want 
people to be accusing them of things, but if people see them sort of hiding it then it gives them a reason 
to accuse them’ (athlete 1: non-asthmatic).
• ‘[Athlete X] got a TUE, will suddenly become, is [athlete X] doping? Not that, oh he’s got a medical condition 
and I think that portrays a lot of club cyclists because they might not know, they’re just the cyclist that 
reads the newspaper that says somebodies taken this and or someone’s had a good performance and they 
might have taken this. I feel like a lot of cyclists will make their own assumptions which might be very 
uneducated assumptions cause they know very little about training or very little about physiological or medical 
conditions and then they’ll go and chat to their friend who isn’t on the group ride and then before you 
know it that group ride is suddenly convinced that this one rider is doping, not because of any hard fact, 
just because they saw an article that they’d taken this or done this’ (athlete 1: non-asthmatic).
• ‘Other athletes who will be using the same medications that [athlete X] is on because they have a medical 
condition, will probably now be, not scared to use it but will be worried about people knowing they use it 
which then I think might make them hide it which then makes it look suspicious even though it’s not but 
it’s just because they’re worried they’ll suddenly get thrown under the bus and people will have a negative 
impact on them…’ (athlete 1: non-asthmatic).
• ‘I think it varies quite a bit; I think there’s certainly a level of you know… I mean you see it in the cycling 
media or just people I’ve ridden with where it’s probably a similar attitude to what I’ve sort of expressed 
previously saying well if they’re winning they’re probably, pushing the right up to the line, they’re winning 
and that there is kind of a real sort of sinisterism about it’ (athlete 5: asthma).
• ‘I think lots of people think that people cheat it… especially when they talk about the Tour de France, it’s 
unusual… the fact that lots have inhalers is dodgy’ (athlete 7: asthma).
• ‘I remember someone saying something about the people the sort of professional perception of how many 
athletes have it and I was like I use the same stuff as them and they get loads of flack’ (athlete 7: asthma).
• ‘Yeh I think having a Ventolin on the start line of the race, I think there are some people that associate 
inhaled salbutamol as a sort of PED [performance enhancing drug]’ (athlete 8: asthma).
• ‘I can only see people taking inhalers, I don’t know about people taking other umm… I’ve only seen a couple 
of people. I think those who race probably can see inhalers being used, so as far as I’m concerned, and I 
think the racers are concerned, I don’t think it’s that bigger issue… I think the public are probably given a 
different idea from the media so…’ (athlete 8: asthma).
• ‘Within the communities in which I circulate it’s something which isn’t really an issue, I think there’s if 
there’s an asthmatic on a ride and someone has a puff on their inhaler there is a lot of jokes that go round 
about enhancing performance umm whether that’s a social ride or that’s a training ride whatever it is but I 
think that’s just the nature of it and I think the stigma around it after some high profile incidents… I think 
there’s always discussion around the famous case, the [athlete X] case and things like that but I don’t think 
it’s something which from my point of view, other people take that seriously certainly in my circle anyway.’ 
(athlete 10: healthy).
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Table 5. Perception of asthma medication in sport (reflexive motivation).
CoDEs athlEtE QuotEs
Stigma • ‘They might have something… amongst the lads it might be a bit of joking like oh here comes the next doper’ 
(athlete 1: non-asthmatic).
• ‘If I saw them just absolutely going to town on it [inhaler], I might feel a little bit different cause I assume 
there’s a limit where the amount that they’re having becomes not just bringing them to a level playing field, it 
takes them up and above’ (athlete 1: non-asthmatic).
• ‘If I was just diagnosed with asthma, I might feel cautious or negative about using it [asthma medication] because 
I’d feel that there is a stigmatism that makes me feel like it’s a bad thing to use. But at the same time, part of 
me feels that everyone else is using it so should it be acceptable for me to use it? Would that make it a level 
playing field? You talk about finding what that level playing field is. I think that’s why it’s so, so hard to measure 
what’s doping and what’s treating a medical condition and what’s stepping up the line. You can’t deny that some-
one doesn’t need a medicine to make their better quality of life but then it’s where that kind of, steps up… edges 
it up’ (athlete 1 non-asthmatic).
• ‘I think if I was competing at a higher level and somebody saw me taking a steroid inhaler before an event, it’d be 
like, hang on that guy has got an advantage, he’s taking an inhaler. I think it definitely depends what level you compete 
and how serious people are taking it. Those-minute kind of advantages actually make a big difference’ (athlete 3: asthma).
• ‘I think there’s a fine line with it. If someone, if someone is losing a little bit of performance from exercise-induced 
asthma and requires a TUE to help them. Like maybe 2%, and it increases themselves up to 100% then that is, 
you know a little bit…what are you doing? If there’s like a big decrease, then they do warrant it. It’s tricky.’ (athlete 
4: non-asthmatic).
• ‘If I have it on the start line someone might make a bit of a joke, but I don’t think anyone’s really too bothered 
you know. It’s not like I’m constantly puffing on it or anything … usually it’s a good place for a joke…usually I 
end up making it myself. There have been times, usually it’s just a mate or something, like “have you a got a TUE 
for that” or something like that, but you know it’s out of good gest’ (athlete 8: asthma).
• ‘I think if you’re just puffing on an inhaler, I’ve no issues with that, but I think I know other asthma drugs that 
some people take that might then have a larger stigma attached’ (athlete 8: asthma).
• ‘I can imagine someone being a bit hesitant taking an asthma inhaler in case they are seen to be wanting to get 
an advantage. I can imagine if I was an asthmatic and I’m stood there on the line taking a couple of puffs on 
my inhaler, I can imagine there are a few people looking around’ (athlete 10: non-asthmatic).
Distrust • ‘I see a lot in the news, it’s really easy to get hold of asthma medication, you just need to go to your GP and 
say x y and z and you can almost get one [inhaler]’ (athlete 1: non-asthmatic).
• ‘you hear of people getting them when they probably don’t need them. They’ve just gone and said what they felt 
would get them, and the GP’s quite readily just gone, well try this it might help you out. Whether that’s just 
kind of Chinese whispers amongst athletes just picking up on using them and then twisting it whatever them-
selves, or just not hearing the full knowledge, might be a case… that’s quite often I find’ (athlete 1: non-asthmatic).
• ‘I think people are getting a little bit like oh well you know there’s a limit and then people are just using the inhalers 
way too much…I think if they used it above their allotted amount, I think there’s definitely…I’ve seen stuff that 
shows you how much it can actually help you; I think they would probably get an advantage from it personally’ 
(athlete 1: non-asthmatic).
• ‘I think there is more to it than just the two people because you can’t have your high-profile names absolutely 
smashing TUEs or taking things in higher doses and then say that no-one else is doing it. So, I think in these 
cases, I imagine everyone’s probably on the TUEs or on the asthma medication, there’s probably more than one 
person doing it’ (athlete 2: non-asthmatic).
• ‘My very uneducated opinion is that the TUEs are too easy to get hold of for athletes, but I don’t really know 
what I’m basing that on. I think I’ve probably heard something somewhere. So yes, I’d say my opinion would 
be that it’s probably too easy to obtain, but again I don’t really know what I’m basing that off ’ (athlete 3: asthma).
• ‘I’m not sure what the real stat is of the pro peloton but the like half of them have TUEs or something. A large 
proportion of them of have TUEs, and it’s like how many of these athletes. How are they all asthmatics? What’s 
going on? (athlete 4: non-asthmatic).
• ‘Depending on whether the team doctors can issue the TUEs too people, probably not. I reckon if someone can 
be made to fit the little bracket that you need to be in to have a TUE, then there obviously not because you 
can manipulate and you can be made to fit in this bracket’ (athlete 4: non-asthmatic).
• ‘I mean some of these contain steroids, when they take them does that give them better muscle building qualities, 
better recovery…’ (athlete 6: asthma).
• They wouldn’t pass a spirometry test, but they have asthma … I think they do push the boundaries and again a 
lot of them are probably taking the asthma medication when they don’t need it and they’ve, the whole, pretty much 
the peloton has asthma. They wouldn’t pass a spirometry test, but they have asthma cause they, they, I’m guessing 
they’re using some sort of asthma steroid to strip the body fat out…’ (athlete 6: asthma).
• ‘I think ingesting salbutamol from what I’ve read can be an effective performance enhancing drug, so if you can claim 
your asthmatic and make use of that then, you know, that may be a sly way of doping in sport’ (athlete 8: asthma).
• ‘There are a lot of asthmatics in the pro peloton… you can say asthmatic with quotation marks you know… I’m 
sure there are ways of using a false asthma medication as a PED [performance enhancing drug]…I’m sure there 
are plenty of genuinely asthmatics in professional cycling, but I reckon a significant proportion… are claiming 
it for a doping purposes’ (athlete 8: non-asthmatic).
• ‘I think even that can be a bit hit and miss, it’s just too easy to fabricate, you know I can go to a doctor and 
say yeh I’ve been really wheezy you and I exercise and I struggle to breath and I get wheezy and it’s like ah yes 
that’s asthma…’ (athlete 8: Asthma).
(Continued)
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has previously been reported to increase the risk of 
misdiagnosis and unnecessary inhaler therapy which 
likely contributes to the widespread perception of 
medication misuse (14,34). Likewise, the challenges 
associated with screening and detection may also add 
to the belief that it is possible to falsify a diagnosis 
and abuse the TUE system. This view was held by 
many athletes in the present study and also perceived 
to exist in the wider sporting community. In-keeping 
with this concept, a previous study in a large cohort 
of Danish athletes (n = 645) reported that over half 
demonstrated distrust toward the TUE system and 
approximately one in ten recalled a period of medi-
cation avoidance despite therapeutic need (35). 
Irrespective of these findings, it should be noted that 
the recently published official WADA report indicates 
that the prevalence of granted TUEs at the Olympic 
Games (between 2010–18) was <1% - with no mean-
ingful association observed with the likelihood of 
winning a medal (36,37).
The media have previously been recognized to 
influence beliefs and behaviors toward anti-doping 
policy and medication use in sport (38,39). In the 
present study, the negative media portrayal of asthma 
medication was described by all athletes with several 
reflecting on recent examples of widely publicized 
asthma-related doping articles concerning high-profile 
elite athletes (40,41). In combination with the afore-
mentioned evidence regarding limited athlete knowl-
edge and concerns over the potential to falsify a 
diagnosis, it is probable that information disseminated 
by the media also contributes to perceptions and/or 
suspicion that some athletes abuse the system. This 
theory aligns with previous findings from a qualitative 
investigation in elite cyclists concerning reports of 
injury falsification in order to obtain medication 
known to optimize performance and/or speed recovery 
(e.g. oral corticosteroid therapy) (42). Of note, the 
majority of athletes in the present study failed to 
discern between the class of medication or route of 
administration when discussing the performance 
enhancing properties of asthma therapy. A lack of 
understanding in this area likely leads to generaliza-
tion and the common misconception that all asthma 
medication constitutes doping and may contribute 
further to medication avoidance or misuse.
Table 5. Continued.
CoDEs athlEtE QuotEs
Acceptance • ‘If they’ve been diagnosed with asthma, I don’t feel like it’s a problem because I’ve seen them taking a few puffs 
of the inhaler. From my experience I’ve only ever seen what I justify as a fair amount. Just a few puffs here and 
there to just open up their lungs, I guess. (athlete 1: non-asthmatic).
• ‘I think it’s justified and if they’re using within the allowed medication limits, I don’t see any problem with it 
at all’ (athlete 1: non-asthmatic).
• ‘if you have some kind of condition where you, you can’t perform to your best without it [medication] then it’s 
unfair, you need to try and make it so everyone’s starting at almost their maximum ability and then they can 
go from there.’ (athlete 4: non-asthmatic).
• ‘He’s a cyclist, he’s got chronic asthma something like that then he should be allowed to use it like. If the inhaler 
doesn’t work for him or something like that, he should be allowed to use something but within limits I suppose 
to not give himself an advantage, a major advantage over competitors’ (athlete 6: asthma).
• ‘At the same time if that is required to make sure that person doesn’t have an asthma attack during the race or 
something like that then that’s obviously worth doing so.’ (athlete 10: non-asthmatic).




• ‘There have been incidences where my asthma has flared up mid-ride, so it happened in Majorca actually on the 
second day. We were doing 5-hours riding but we’d been out for hours and it was pretty dry, and I wasn’t used 
to it. My asthma really started to play up to the extent where my breathing became really shallow and that did 
impact my ability to ride so I nearly got dropped going up one of the last climbs’ (athlete 3: asthma).
• ‘We go to the alps every year and I really have to use it there because the airs thinner and really notice that I 
can’t breath as well and if I don’t do a warm up, all the other people around even though, even people that 
normally are not nearly the same pace as me, they can deal fine and ride quite fast up the mountains without 
a warm up whereas if I don’t get a warm I literally have to stop after like 5 min’ (athlete 7: asthma).
• ‘One year I had a really bad flare up going up Alpe d’Huez where we didn’t warm up because we were living 
right at the bottom of it and we tried to go up Alpe d’Huez and then I had to stop and I was really upset and 
I was wheezing loads and I had to go home because I couldn’t get it back under control’ (athlete 7: asthma).
Risk of
exacerbation
• ‘When I see guys at the club taking it, that shows that you’re concerned your asthma is going to flare up’ (athlete 
3: asthma).
• ‘I don’t like trying to cycle hard if I’m feeling asthmatic’ (athlete 5: asthma).
• ‘You know that it’s going to bother you, so you put it in your tri suit for the run’ (athlete 7: asthma).
• ‘I’m not sure, as far as I know it could be placebo more than anything else, but I think it helps me, like at least 
if I’ve got it I don’t have to worry about it, I’m not worrying about having to have a puff on my inhaler you 
know, I haven’t got that extra stress… I can get a bit stressed and worried If I don’t have it… I might do an 
effort and I might find that I need it just to help keep my lungs open’ (athlete 8: asthma).
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Implementing targeted behavioral interventions
The findings of this study underscore the need for 
interventions that enable optimal medication adher-
ence to preserve athlete respiratory health and protect 
the integrity of sport. Based on these findings, edu-
cational programmes should aim to address athlete 
knowledge and the negative stigma attached to the 
use of asthma therapy. Improving knowledge and 
understanding of the health and performance impli-
cations of asthma medication, alongside anti-doping 
regulations and rule-violations, will likely improve the 
capability and motivation for adherence. Moving for-
ward, educational programmes should be directed 
toward primary care physicians and athlete support 
personnel (i.e. sports medics and coaches etc.), in 
whom knowledge may be comparably limited, to 
improve athlete support and increase self-efficacy 
toward medication and anti-doping policy (33,43). 
Whilst the funding for education within anti-doping 
organizations is often limited (43,44), the high prev-
alence of asthma among athletes (45) warrants 
increased commitment to the development of acces-
sible resources. In this respect, increasing referrals to 
respiratory specialists may improve the care afforded 
to athletes reporting breathing difficulty (46). Indeed, 
long-term widespread use of sub-optimal diagnostic 
methods may continue to reinforce the belief that 
TUEs and medication are open to abuse. In addition, 
there is an urgent need to address the widespread 
negative stigma toward asthma medication within the 
athletic community. Although it is important to avoid 
compromising athlete confidentially (i.e. medical 
records), increasing the transparency of medication 
use and TUEs may help reduce the growing percep-
tion of wrongdoing (1).
Methodological considerations and future 
research
Adopting a relativist, rather than a criteriological 
approach (47), we sought to build credibility and trust-
worthiness of the data and exemplify our contribution 
to the field, by drawing upon markers of quality in 
qualitative research (48). For example, worthiness of 
the topic and qualitative methodology is illustrated in 
the pertinence of asthma medication adherence, avoid-
ance and misuse within the field of sport science and 
medicine, and the complexities of athlete behavior (49), 
respectively. Indeed, for the first time, the use of estab-
lished qualitative methodology elicited direct quota-
tions from multiple perspectives, revealing numerous 
barriers to optimal athlete health that are of signifi-
cance to the implementation of evidence-based behav-
ior change strategies. Rich rigor was ensured by the 
transparency of the data analysis process and the 
recruitment of an appropriate athlete sample to meet 
the study aims. Whilst it is acknowledged that the 
present study sample is not demographically diverse, 
and the sample size is smaller than those typically 
found in quantitative research studies, statistical gen-
eralizability and large sample sizes are not germane to 
qualitative research (50). Rather, this study achieves 
transferability through the detailed methodological 
description and presentation of all data (48), that 
enables readers to interpret the study findings in rela-
tion to their individual context. Indeed, these novel 
athlete accounts and the patterns of talk generated 
highlight the need to elicit further questioning and 
initiate further investigations in recreational and elite 
athlete populations, and support personnel.
Conclusion
In summary, the novel application of behavioral science 
highlights several factors that potentially interact to 
contribute to asthma medication avoidance and promote 
misuse in competitive sport. The findings from this 
study provide a foundation for the development and 
implementation of targeted education programmes, and 
it is hoped that employing this approach will improve 
overall perceptions of asthma treatment in athletes, 
which is necessary to maintain respiratory health, opti-
mize performance and protect the integrity of sport.
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